Europe Diabetes Devices and Therapeutics Market Investment Opportunities – Analysis & Market Size by Diagnosis and Monitoring Devices, Therapeutics, Combination Drugs, Route of Administration, Type of Diabetes, Distribution Channels, End User, Competitiv

According to BioIntel360, diabetes market in Europe is expected to grow by 9.5% on annual basis to reach US$23,783.1 million in 2025.

The diabetes market in the region has experienced robust growth during 2020-2024, achieving a CAGR of 10.3%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 8.0% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 21,716.2 million to approximately USD 35,272.3 million.

Key Trends and Drivers in Europe's Diabetes Devices and Therapeutics Market
Europe's diabetes devices and therapeutics market is evolving due to rising disease prevalence, increased digital health integration, and refined regulatory frameworks. These trends will intensify over the next 2–4 years, leading to a more data-informed and policy-aligned approach to diabetes management across Europe.

Address Increasing Diabetes Prevalence and Demographic Shifts
• Recent studies from European public health bodies highlight a rise in diabetes prevalence, particularly in countries such as Germany, the United Kingdom, and Italy. Data indicates that aging populations and urban lifestyle factors contribute to this upward trend.
• Changing demographics and evolving healthcare policies are intensifying the demand for effective diabetes management. National healthcare initiatives and insurance adjustments are prompting wider access to monitoring devices and therapies.
• Demand for both diagnostic and therapeutic solutions is expected to grow steadily. Healthcare systems will likely prioritize resource allocation toward long-term diabetes management, leading to incremental market expansion.

Advance Digital Integration and Remote Monitoring Adoption
• Recent publications reveal an accelerated uptake of continuous glucose monitoring (CGM) systems and telemedicine services in countries such as France and Spain. Several European healthcare settings have initiated pilot programs integrating data-driven management tools with routine care.
• Progress in digital health technology and a supportive regulatory framework are central to this trend. Investments in digital infrastructure and data analytics by both public and private sectors are enhancing remote monitoring capabilities.
• The role of digital solutions in clinical decision-making is expected to strengthen, supporting personalized patient management. Real-time data integration will likely improve disease monitoring and therapy adjustments, embedding digital tools in standard care.

Strengthen Regulatory Reforms and Reimbursement Strategies
• Recent reforms in the European Union and individual member states have revised the regulatory landscape for medical devices, including diabetes management tools. Updated reimbursement policies in nations like the United Kingdom and Germany now provide clearer pathways for adopting new technologies.
• Policy updates aimed at cost-containment and improved clinical outcomes are driving these regulatory changes. Collaboration between healthcare authorities and insurers is streamlining market access for newer devices and therapies.
• Continued regulatory adjustments and enhanced reimbursement models are expected to promote steady market growth. Clarity in approval processes and funding will likely accelerate the adoption of emerging diabetes management solutions.

Competitive Landscape in Europe's Diabetes Devices and Therapeutics Market
The European market for diabetes devices and therapeutics is characterized by a mix of long-established firms and emerging local players adapting to regional needs. With a trend toward strategic partnerships and market consolidation, the next 2–4 years will likely see a reshaped competitive landscape emphasizing localized development and regulatory alignment.

Assess Current Market Conditions and Dynamics
• The market includes established multinational corporations alongside local manufacturers focusing on the European regulatory environment. Recent publications indicate a diverse market structure with varied product portfolios responding to local clinical and cost needs.

Key Players and Emerging Entrants
• Major firms continue to maintain strong positions through ongoing research and development, catering to high-standard regulatory requirements in Europe.
• Local companies, particularly in Scandinavia and Southern Europe, are developing solutions that align with regional clinical practices and budget constraints.
• Recent market reports note the entrance of technology-focused startups seeking to address gaps in continuous monitoring and patient data management.

Execute Strategic Collaborations and Monitor Consolidation Trends
• Recent transactions have seen collaborations between device manufacturers and healthcare service providers across various European markets.
• As documented in recent industry analyses, strategic mergers and acquisitions aim to enhance product portfolios and expand regional reach.
• The competitive landscape is projected to experience further consolidation, with established players potentially partnering with or acquiring local innovators.
• Firms that navigate the evolving regulatory framework and invest in localized development are expected to secure lasting competitive advantages.

This report provides a detailed data-centric analysis of the diabetes industry in Europe, covering market opportunities and analysis across a range of diagnosis and monitoring devices, therapeutics, domains. With over 50+ KPIs at the country level, this report provides a comprehensive understanding of diabetes market dynamics, market size and forecast, and market share statistics.

BioIntel360’s research methodology is based on industry best practices. Its unbiased analysis leverages a proprietary analytics platform to offer a detailed view of emerging business and investment market opportunities.

This title from BioIntel360 is a bundled offering, combining the following 14 reports, covering 560 tables and 756 figures:

1. Europe Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook)
2. Austria Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook)
3. Belgium Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook)
4. Denmark Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook)
5. France Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook)
6. Germany Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook)
7. Ireland Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook)
8. Italy Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook)
9. Netherlands Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook)
10. Poland Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook)
11. Russia Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook)
12. Spain Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook)
13. Switzerland Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook)
14. United Kingdom Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook)

Scope

This report provides an in-depth, data-centric analysis of the Europe diabetes devices and therapeutics market 2020-2029. Below is a summary of key market segments:

Diabetes Devices and Therapeutics Market Share by Category
• Diagnosis and Monitoring Devices
• Therapeutics

Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices
• Blood Glucose Monitoring Devices
• Insulin Delivery Devices
• Diabetes Management and Mobile Applications
• Artificial Pancreas Devices

Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices
• Self-Monitoring Blood Glucose Devices
• Continuous Blood Glucose Monitoring Devices
• Test Strips
• Lancets

Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices
• Insulin Pumps
• Insulin Pens
• Insulin Syringes

Diabetes Devices and Therapeutics Market Share by Therapeutics
• Oral Anti-Diabetic Drugs
• Insulin
• Non-Insulin Injectable Drugs
• Combination Drugs

Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs
• Alpha-Glucosidase Inhibitors
• DPP-4 Inhibitors
• SGLT-2 Inhibitors

Diabetes Devices and Therapeutics Market Share by Insulin
• Basal or Long-Acting
• Bolus or Fast-Acting
• Traditional Human Insulin Drugs
• Insulin Biosimilars

Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs
• GLP-1 Receptor Agonists
• Amylin Analogue

Diabetes Devices and Therapeutics Market Share by Combination Drugs
• Combination Insulin
• Oral Combination

Diabetes Devices and Therapeutics Market Share by Route of Administration
• Subcutaneous
• Intravenous
• Others

Diabetes Devices and Therapeutics Market Share by Type of Diabetes
• Type 1 Diabetes
• Type 2 Diabetes

Diabetes Devices and Therapeutics Market Share by Distribution Channels
• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

Diabetes Devices and Therapeutics Market Share by End User
• Hospitals
• Diabetes Clinics
• Homecare

Reasons to Buy

• Comprehensive understanding of market structure and dynamics: Gain a detailed view of the diabetes devices and therapeutics market, including category-level segmentation (Diagnosis & Monitoring Devices and Therapeutics) and sub-segmentation by product type, route of administration, type of diabetes, distribution channel, and end user.

• Identify high-growth segments and strategic investment areas: Use segment-wise market sizing and forecasting to identify opportunities in areas such as continuous glucose monitoring, insulin delivery technologies, oral anti-diabetic drugs, and biosimilars. Tailor your market entry or expansion strategies accordingly.

• Benchmark performance across distribution and care settings: Access share analysis across online, hospital, and retail pharmacies, and evaluate usage patterns across hospitals, diabetes clinics, and homecare to support channel-specific planning and resource allocation. Show more